[Corrigendum] Daily or weekly dosing with EGFR inhibitors, gefitinib and lapatinib, and AKT inhibitor MK2206 in mammary cancer models.

Name: [Corrigendum] Daily or weekly dosing with EGFR inhibitors, gefitinib and lapatinib, and AKT inhibitor MK2206 in mammary cancer models.
Author: Lubet, Ronald A

[Corrigendum] Daily or weekly dosing with EGFR inhibitors, gefitinib and lapatinib, and AKT inhibitor MK2206 in mammary cancer models. — المؤلف: Lubet, Ronald A — Oncology reports 20181228

المؤلف: Lubet, Ronald A
النشر: Oncology reports 20181228
الوصف: 718 p.